Yesafili
Yesafili ingredients
| Active ingredient | Strength |
|---|---|
| Aflibercept | 2 mg/.05mL |
What Yesafili is used for
The FDA lists the approved uses on the official label (below). In the EU, aflibercept is approved as Zaltrap for:
Treatment of metastatic colorectal cancer (MCRC).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Yesafili
- Generic name
- Aflibercept-jbvf
- Made by
- Biocon Biologics Inc.
- Forms
- Injection, Solution
- Given
- Intravitreal
- Drug class
- Vascular Endothelial Growth Factor Inhibitor
- FDA approval
- Biologic licence (BLA) BLA761274
- On the US market since
- 2026
Official information
- MedlinePlus drug information (search for Aflibercept-jbvf)
In India
- Aflibercept: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Yesafili?
Yesafili (Aflibercept-jbvf) is a cancer medicine made by Biocon Biologics Inc., approved by the US FDA.
What are the ingredients of Yesafili?
Yesafili contains Aflibercept (2 mg/.05mL).
Is Yesafili approved in Europe?
The same active substance is approved in the EU as Zaltrap.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA